StreetInsider.com News Articles

Form 144 QUEST DIAGNOSTICS INC Filed by: Doherty Catherine T.

Tue, 03 Nov 2026 10:10:00 -0500

si-local-file:///var/storage/secattach/20261103/27279144.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 26 Filed by: PFEIFFER GARY M

Wed, 28 Oct 2026 18:06:00 -0500

si-local-file:///var/storage/secattach/20261028/27250573.html

Form 144 QUEST DIAGNOSTICS INC Filed by: PFEIFFER GARY M

Mon, 26 Oct 2026 09:47:00 -0500

si-local-file:///var/storage/secattach/20261026/27231949.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 21 Filed by: Gregg Vicky B

Fri, 23 Oct 2026 19:33:00 -0500

si-local-file:///var/storage/secattach/20261023/27228818.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 21 Filed by: SAMAD SAM

Fri, 23 Oct 2026 19:33:00 -0500

si-local-file:///var/storage/secattach/20261023/27228819.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 21 Filed by: CARTER ROBERT B

Fri, 23 Oct 2026 19:33:00 -0500

si-local-file:///var/storage/secattach/20261023/27228820.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 21 Filed by: Plewman Patrick

Fri, 23 Oct 2026 19:32:00 -0500

si-local-file:///var/storage/secattach/20261023/27228815.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 21 Filed by: Lassiter Wright III

Fri, 23 Oct 2026 19:32:00 -0500

si-local-file:///var/storage/secattach/20261023/27228816.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 21 Filed by: KUPPUSAMY KARTHIK

Fri, 23 Oct 2026 19:32:00 -0500

si-local-file:///var/storage/secattach/20261023/27228817.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 21 Filed by: DELANEY MARK E

Fri, 23 Oct 2026 19:31:00 -0500

si-local-file:///var/storage/secattach/20261023/27228813.html

Form 4 QUEST DIAGNOSTICS INC For: Oct 21 Filed by: MAIN TIMOTHY L

Fri, 23 Oct 2026 19:31:00 -0500

si-local-file:///var/storage/secattach/20261023/27228814.html

Form 10-Q QUEST DIAGNOSTICS INC For: Sep 30

Fri, 23 Oct 2026 16:18:00 -0500

si-local-file:///var/storage/secattach/20261023/27228088.html

Quest Diagnostics (DGX) PT Raised to $262 at Baird

Fri, 23 Oct 2026 06:44:45 -0500

Baird analyst Eric Coldwell raised the price target on Quest Diagnostics (NYSE: DGX) to $262.00 (from $260.00) while maintaining a Neutral rating.

Quest Diagnostics reports unauthorized access to patient records system

Thu, 22 Oct 2026 06:55:51 -0500

Quest Diagnostics (NYSE: DGX) disclosed that on October 21, 2026, an unauthorized party gained access to its Quanum LSM system, a platform used by certain clients to place test orders and retrieve results.

The company stated it initiated cybersecurity incident response procedures upon learning of the breach, and has notified federal law enforcement authorities. External cybersecurity experts have been engaged to assist in the investigation.

Quest Diagnostics said the full scope of the unauthorized access remains under investigation, but believes certain patient records were accessed. The company added that the incident has not materially disrupted its business operations or its ability to

Form 8-K QUEST DIAGNOSTICS INC For: Oct 21

Thu, 22 Oct 2026 06:54:00 -0500

si-local-file:///var/storage/secattach/20261022/27218632.html

Form 8-K QUEST DIAGNOSTICS INC For: Oct 22

Thu, 22 Oct 2026 06:50:00 -0500

si-local-file:///var/storage/secattach/20261022/27218624.html

Quest Diagnostics (DGX) Tops Q3 EPS by 13c; raises guidance

Thu, 22 Oct 2026 06:47:57 -0500

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $3.00, $0.13 better than the analyst estimate of $2.87. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $3.05 billion.

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $11.25-$11.35, versus the consensus of $11.20. Quest Diagnostics sees FY2026 revenue of $12.065-12.105 billion, versus the consensus of $12.016 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

Quest Diagnostics (DGX) Tops Q3 EPS by 13c; raises guidance

Thu, 22 Oct 2026 06:47:57 -0500

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $11.25-$11.35, versus the consensus of $11.20. Quest Diagnostics sees FY2026 revenue of $12.065-12.105 billion, versus the consensus of $12.016 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Thu, 22 Oct 2026 06:46:00 -0500

Third quarter revenues of $3.10 billion, up 10.0% from 2025, on strong organic revenue growth
Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025

Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Thu, 22 Oct 2026 06:46:00 -0500

Third quarter revenues of $3.10 billion, up 10.0% from 2025, on strong organic revenue growth
Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Tue, 20 Oct 2026 08:00:00 -0500

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027
First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Tue, 20 Oct 2026 08:00:00 -0500

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027
First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Tue, 20 Oct 2026 08:00:00 -0500

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027
First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Tue, 20 Oct 2026 08:00:00 -0500

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027
First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive

Quest Diagnostics (DGX) PT Raised to $250 at UBS

Mon, 19 Oct 2026 09:12:17 -0500

UBS analyst Kevin Caliendo raised the price target on Quest Diagnostics (NYSE: DGX) to $250.00 (from $245.00) while maintaining a Neutral rating.